Skip to main content
Alteogen Inc. logo

Alteogen Inc. — Investor Relations & Filings

Ticker · 196170 ISIN · KR7196170005 KO Professional, scientific and technical activities
Open in API
Filings indexed 293 across all filing types
Latest filing 2020-04-09 Director's Dealing
Country KR South Korea
Listing KO 196170

About Alteogen Inc.

http://www.alteogen.com/

Alteogen Inc. is a biopharmaceutical company focused on the development and commercialization of next-generation biologics. The company's core activities are centered on its proprietary platform technologies. These include Hybrozyme™, a novel recombinant human hyaluronidase (ALT-B4) technology that enables the conversion of intravenous (IV) therapies to subcutaneous (SC) formulations, enhancing patient convenience. Additionally, Alteogen develops long-acting biobetters utilizing its NexP™ fusion technology, proprietary antibody-drug conjugates (ADCs), and antibody biosimilars. The company's pipeline is aimed at creating therapies with enhanced efficacy and delivery methods for serious diseases.

Recent filings

Filing Released Lang Actions
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서). This is a standard regulatory filing in South Korea (DART system) where company insiders report their personal share transactions or changes in ownership. This falls under the category of Director's Dealing (DIRS), which covers reports of personal share transactions by company directors and executives.
2020-04-09 Korean
기타경영사항(특허권취득)(자율공시)
Regulatory Filings Classification · 95% confidence The document is a regulatory disclosure from Alteogen regarding the acquisition of a patent for a stable liquid formulation of a fusion protein. It is filed under '기타 경영사항(특허권 취득)(자율공시)', which translates to 'Other Management Matters (Patent Acquisition) (Voluntary Disclosure)'. Since this is a specific corporate announcement regarding a material business development (patent acquisition) that does not fit into financial reporting, M&A, or governance categories, it falls under the general regulatory filing category.
2020-04-03 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding), which is a standard regulatory filing in South Korea under the Capital Markets Act. It details changes in share ownership by major shareholders and special related parties (insider transactions, changes in status). This type of filing is specifically categorized as a 'Major Shareholding Notification' (MRQ) in the provided schema.
2020-04-01 Korean
사업보고서 (2019.12)
Annual Report Classification · 100% confidence The document is a 'Business Report' (사업보고서) for the fiscal year 2019, covering the period from January 1, 2019, to December 31, 2019. It includes detailed financial information, company history, capital structure, and business operations. In the context of Korean regulatory filings (DART), a 'Business Report' (사업보고서) is the equivalent of an Annual Report (10-K). FY 2019
2020-03-30 Korean
정기주주총회결과
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is an official report of the results of an Annual General Meeting (AGM) for the company Alteogen. It details the approval of financial statements, election of directors and auditors, and other resolutions passed during the meeting held on March 26, 2020. This fits the definition of 'Declaration of Voting Results & Voting Rights Announcements' (DVA) as it provides the official outcome of shareholder votes at the general meeting.
2020-03-26 Korean
주식매수선택권부여에관한신고
Share Issue/Capital Change Classification · 95% confidence The document is a formal regulatory filing titled '주식매수선택권 부여에 관한 신고' (Report on the Granting of Stock Options) submitted to the Financial Services Commission/Korea Exchange. It details the issuance of stock options to employees, including the number of shares, exercise price, and valuation methodology. This type of disclosure regarding capital structure changes and employee compensation via stock options falls under the category of 'Share Issue/Capital Change' (SHA) as it relates to the potential issuance of new shares or treasury shares.
2020-03-26 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.